MEC (mitoxantrone, etoposide and intermediate dose cytarabine): An effective induction regimen for previously untreated acute non-lymphocytic leukemia

G. Visani, M. C. Petti, A. Cenacchi, S. Manfroi, P. Tosi, A. Spadea, R. Latagliata, S. Amadori, F. Mandelli, S. Tura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.

Original languageEnglish
Pages (from-to)447-451
Number of pages5
JournalLeukemia and Lymphoma
Volume19
Issue number5-6
DOIs
Publication statusPublished - 1995

Fingerprint

Mitoxantrone
Cytarabine
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Intravenous Infusions
Recurrence

Keywords

  • Acute myeloid leukemia
  • Intermediate dose cytarabine
  • Mitoxantrone
  • Remission
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

MEC (mitoxantrone, etoposide and intermediate dose cytarabine) : An effective induction regimen for previously untreated acute non-lymphocytic leukemia. / Visani, G.; Petti, M. C.; Cenacchi, A.; Manfroi, S.; Tosi, P.; Spadea, A.; Latagliata, R.; Amadori, S.; Mandelli, F.; Tura, S.

In: Leukemia and Lymphoma, Vol. 19, No. 5-6, 1995, p. 447-451.

Research output: Contribution to journalArticle

Visani, G. ; Petti, M. C. ; Cenacchi, A. ; Manfroi, S. ; Tosi, P. ; Spadea, A. ; Latagliata, R. ; Amadori, S. ; Mandelli, F. ; Tura, S. / MEC (mitoxantrone, etoposide and intermediate dose cytarabine) : An effective induction regimen for previously untreated acute non-lymphocytic leukemia. In: Leukemia and Lymphoma. 1995 ; Vol. 19, No. 5-6. pp. 447-451.
@article{bc9b9fa327534909a9f4b37d72d351a8,
title = "MEC (mitoxantrone, etoposide and intermediate dose cytarabine): An effective induction regimen for previously untreated acute non-lymphocytic leukemia",
abstract = "Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9{\%} obtained CR, five patients (22.7{\%} were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.",
keywords = "Acute myeloid leukemia, Intermediate dose cytarabine, Mitoxantrone, Remission, Survival",
author = "G. Visani and Petti, {M. C.} and A. Cenacchi and S. Manfroi and P. Tosi and A. Spadea and R. Latagliata and S. Amadori and F. Mandelli and S. Tura",
year = "1995",
doi = "10.3109/10428199509112203",
language = "English",
volume = "19",
pages = "447--451",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "5-6",

}

TY - JOUR

T1 - MEC (mitoxantrone, etoposide and intermediate dose cytarabine)

T2 - An effective induction regimen for previously untreated acute non-lymphocytic leukemia

AU - Visani, G.

AU - Petti, M. C.

AU - Cenacchi, A.

AU - Manfroi, S.

AU - Tosi, P.

AU - Spadea, A.

AU - Latagliata, R.

AU - Amadori, S.

AU - Mandelli, F.

AU - Tura, S.

PY - 1995

Y1 - 1995

N2 - Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.

AB - Twenty-three patients with acute nor1 lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2 day and intermediate dose Cytarabine (ara-C) Ig/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-course of MEC as consolidation. Seventeen patients (73.9% obtained CR, five patients (22.7% were resistant to the treatment and one patient died during induction. Median remission duration was 11 months; overall median survival was 16 months. Relapses occurred in 11 patients; eight patients are still alive: 6 in 1st, 2 in 2nd CR (mean survival 20.1 months, range 17-26). All patients experienced severe myelosuppression comparable to that observed after classical induction cycles including ara-C in continuous intravenous infusion; none, however, died of infection. Non-hematologic toxicity was minimal; in particular, neurotoxicity was not observed. According to our results, the MEC regimen, which was previously demonstrated to be active in refractory patients, represents an effective induction treatment in ANLL, with an acceptable toxicity.

KW - Acute myeloid leukemia

KW - Intermediate dose cytarabine

KW - Mitoxantrone

KW - Remission

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0028972612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028972612&partnerID=8YFLogxK

U2 - 10.3109/10428199509112203

DO - 10.3109/10428199509112203

M3 - Article

C2 - 8590845

AN - SCOPUS:0028972612

VL - 19

SP - 447

EP - 451

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -